To clarify the media report
1.Date of occurrence of the event:2016/06/06 2.Company name: OBI Pharma, Inc. 3.Relationship to the Company (please enter ”head office” or ”affiliatecompany”): The Company head office 4.Reciprocal shareholding ratios: N/A 5.Name …
The company will publish the clinical study data of the innovation research of OBI-822/OBI-821 for metastatic breast cancer patients at the annual meeting of 2016 ASCO.
1.Date of occurrence of the event:2016/06/05 2.Company name: OBI Pharma, Inc. 3.Relationship to the Company (please enter ”head office” or ”affiliatecompany”): The Company head office 4.Reciprocal shareholding ratios: N/A 5.Name …
OBI Pharma Presents Data for Novel Investigational OBI-822/OBI-821 in Patients with Metastatic Breast Cancer at the 2016 American Society of Clinical Oncology Annual Meeting
Results from Phase II/III Clinical Trials Show Improvement in Subset of Patients who Developed an Immune Response to Vaccination TAIPEI, TAIWAN, June 04, 2016 — OBI Pharma, Inc., a Taiwan …
Announcement of the Company holding investor presentation and Significant post press conference
1.Date of occurrence of the event:2016/05/30 2.Company name: OBI Pharma, Inc. 3.Relationship to the Company (please enter ”head office” or ”affiliatecompany”): The Company head office 4.Reciprocal shareholding ratios: N/A 5.Name …
Company will hold the Investor Conference
1.Date of the investor conference:2016/06/05 2.Time of the investor conference:2:00 p.m.(Taiwan Time) 3.Location of the investor conference: 11F., No.97, Sec. 2, Dunhua S. Rd., Da’an Dist., Taipei City 106, Taiwan …
The company states the media’s reports on the related matters of American Society of Clinical Oncology (ASCO).
1.Date of occurrence of the event:2016/05/29 2.Company name: OBI Pharma, Inc. 3.Relationship to the Company (please enter ”head office” or ”affiliatecompany”): The Company head office 4.Reciprocal shareholding ratios: N/A 5.Name …
Media reports that Michael Chang, the chairman of the company, Amy Huang, the general manager and the staffs, six people in total, were guaranteed pending summons for alleged insider trading.
1.Date of occurrence of the event:2016/05/26 2.Company name: OBI Pharma, Inc. 3.Relationship to the Company (please enter ”head office” or ”affiliatecompany”): The Company head office 4.Reciprocal shareholding ratios: N/A 5.Name …
Publication of the Breast Cancer Study Abstract to be presented at ASCO 2016
1.Date of occurrence of the event:2016/05/19 2.Name of the company: OBI Pharma, Inc. 3.Relationship to the Company (please enter ”head office” or ”affiliate company”): The Company head office 4.Reciprocal shareholding …
OBI’s Abstract at ASCO 2016: Randomized Phase 2/3 Trial of Active Immunotherapy With OPT-822/OPT-821 in Patients With Metastatic Breast Cancer
Background: Globo H is a glycolipid that is highly expressed in breast cancer (BC). Active immunotherapy with OPT-822, a Globo H-KLH conjugate, and the adjuvant OPT-821 in two phase 1 …
OBI Pharma to Present New Data at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
Oral Presentation Highlights the Results of a Phase II/III Trial of the Investigational Immunotherapy OBI-822/OBI-821 in Patients with Metastatic Breast Cancer TAIPEI, TAIWAN, May 19, 2016 – OBI Pharma, Inc., …